share_log

Walgreens Boots Alliance | 8-K: Walgreens Boots Alliance Reports Fiscal 2024 Third Quarter Results

Walgreens Boots Alliance | 8-K: Walgreens Boots Alliance Reports Fiscal 2024 Third Quarter Results

沃爾格林-聯合博姿 | 8-K:沃爾格林靴子聯盟公佈2024財年第三季度業績
美股SEC公告 ·  2024/06/27 06:08

Moomoo AI 已提取核心訊息

Walgreens Boots Alliance reported Q3 FY2024 sales of $36.4 billion, up 2.6% YoY, while adjusted EPS declined 36.6% to $0.63, impacted by lower sale-leaseback gains and challenging U.S. retail environment. The company lowered its FY2024 adjusted EPS guidance to $2.80-$2.95 due to persistent pharmacy margin pressures and weak consumer spending.The company announced strategic initiatives including optimization of U.S. store footprint, launching retail pharmacy action plan, and simplifying healthcare portfolio. Q3 operating income was $111 million compared to a loss of $477 million last year. U.S. Retail Pharmacy segment saw comparable sales increase of 3.5%, while International segment grew 2.8%.Free cash flow improved to $334 million, up $778 million YoY, driven by working capital optimization and reduced capital expenditures. The U.S. Healthcare segment achieved positive adjusted EBITDA of $23 million, marking second consecutive quarter of profitability improvement.
Walgreens Boots Alliance reported Q3 FY2024 sales of $36.4 billion, up 2.6% YoY, while adjusted EPS declined 36.6% to $0.63, impacted by lower sale-leaseback gains and challenging U.S. retail environment. The company lowered its FY2024 adjusted EPS guidance to $2.80-$2.95 due to persistent pharmacy margin pressures and weak consumer spending.The company announced strategic initiatives including optimization of U.S. store footprint, launching retail pharmacy action plan, and simplifying healthcare portfolio. Q3 operating income was $111 million compared to a loss of $477 million last year. U.S. Retail Pharmacy segment saw comparable sales increase of 3.5%, while International segment grew 2.8%.Free cash flow improved to $334 million, up $778 million YoY, driven by working capital optimization and reduced capital expenditures. The U.S. Healthcare segment achieved positive adjusted EBITDA of $23 million, marking second consecutive quarter of profitability improvement.
2024年6月27日,Walgreens Boots Alliance,Inc. (WBA)公佈其截至2024年5月31日的財季財務業績。該公司宣佈,調整後每股收益按常態貨幣計算與去年相比下降了36.6%,原因是較低的出售租賃收益,具有挑戰性的美國零售環境以及近期藥房行業趨勢等因素造成。儘管面臨這些挑戰,第三財季銷售額同比增長了2.6%,達到364億美元。WBA還將其2024財年調整後的EPS指導下調至2.80至2.95美元,反映了持續存在的行業挑戰和預期之外的美國消費環境惡化。此外,該公司正在最終確定一項重大的多年足跡優化計劃,關閉某些表現不佳的美國商店,並啓動美國零售藥店行動計劃,以投資和改善客戶和患者體驗。該公司首席執行官Tim Wentworth對團隊和策略領導業務回升充滿信心。該財務報告還伴隨着一次會議呼叫和網絡廣播,討論結果及相關事宜。
2024年6月27日,Walgreens Boots Alliance,Inc. (WBA)公佈其截至2024年5月31日的財季財務業績。該公司宣佈,調整後每股收益按常態貨幣計算與去年相比下降了36.6%,原因是較低的出售租賃收益,具有挑戰性的美國零售環境以及近期藥房行業趨勢等因素造成。儘管面臨這些挑戰,第三財季銷售額同比增長了2.6%,達到364億美元。WBA還將其2024財年調整後的EPS指導下調至2.80至2.95美元,反映了持續存在的行業挑戰和預期之外的美國消費環境惡化。此外,該公司正在最終確定一項重大的多年足跡優化計劃,關閉某些表現不佳的美國商店,並啓動美國零售藥店行動計劃,以投資和改善客戶和患者體驗。該公司首席執行官Tim Wentworth對團隊和策略領導業務回升充滿信心。該財務報告還伴隨着一次會議呼叫和網絡廣播,討論結果及相關事宜。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息